Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome

Environmental Health Perspectives

Volumn 109, Issue 4, 2001, Pages 369-375

  Ladona, Margarita G ^a,d   Izquierdo Martinez, Maravillas ^b   Posada De La Paz, Manuel ^c   De La Torre, Rafael ^a   Ampurdanés, Coral ^a,d   Segura, Jordi ^a   Sanz, Emilio J ^e  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d DEPT OF ENVIRONMENTAL CHEMISTRY   (Spain)

^e UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

CYP1A1; CYP2D6; Enzyme genetic polymorphisms; GSTM1; GSTT1; Molecular epidemiology; NAT2; Spanish toxic oil syndrome; Xenobiotic metabolism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; ENZYME; GLUTATHIONE TRANSFERASE; RAPESEED OIL; XENOBIOTIC AGENT;

ACETYLATION; ADULT; AGE; ALLELE; ARTICLE; CASE CONTROL STUDY; CONJUGATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME POLYMORPHISM; FEMALE; GENDER; GENOTYPE; HUMAN; MALE; METABOLIC CAPACITY; PHARMACOGENETICS; PRIORITY JOURNAL; SIBLING; SPAIN; SURVIVAL; TOXIC OIL SYNDROME; XENOBIOTIC METABOLISM;

SINAPIS ARVENSIS; TOSCANA VIRUS;

EID: 0035011225     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.01109369     Document Type: Article

References (71)

1. Grandjean P, Tarkowski S, eds. Toxic Oil Syndrome: Mass Food Poisoning in Spain: Report of a WHO Meeting, Madrid, 21-25 March 1983. Copenhagen:World Health Organization, Regional Office for Europe, 1984.
2. Posada de la Paz M. Diet and food contaminants. In: Topics in Environmental Epidemiology (Kyle S, Savitz DA, eds). NewYork:Oxford University Press, 1997;64-88.
3. Tabuenca JM. Toxic allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 2:567-568 (1981).
4. Rigau-Perez JG. Summary of case-control studies and case or cluster investigations. In: Toxic Oil Syndrome: Mass Food Poisoning in Spain: Report of a WHO Meeting, Madrid, 21-25 March 1983 (Gradjean P, Tarkowski S, eds). Copenhagen:World Health Organization, Regional Office for Europe, 1984:47-51.
5. Rigau-Perez JG, Perez-Alvarez L, Duenas-Castro S, Choi K, Thacker SB, Germain JL, Gonzalez-de-Andres G, Canada-Royo L, Perez-Gallardo F. Epidemiologic investigation of an oil-associated pneumonic paralytic eosinophilic syndrome in Spain. Am J Epidemiol 119:250-260 (1984).
6. Díaz de Rajas F, Castro-Garcia M, Abaitua Borda I, Alonso Gordo JM, Posada de la Paz M, Kilbourne EM, Tabuenca Oliver JM. The association of oil ingestion with toxic oil syndrome in two convents. Am J Epidemiol 125:907-911 (1987).
7. Canas R, Kilbourne EM. Oil ingestion and the toxic oil syndrome: results of a survey of residents of the Orcasur neighbourhood in Madrid, Spain. Int J Epidemiol 16:3-6 (1987).
8. Abaitua-Borda I, Philen R, Posada de la Paz M, Gómez de la Cámara A, Díez Ruiz-Navarro M, Giménez Ribota O, Alvargonzalez Soldevilla J, Terracini B, Severiano Pena S, Fuentes Leal C, et al. Toxic oil syndrome mortality: the first 13 years. Int J Epidemiol 27:1557-1063 (1998).
9. Abaitua-Borda I, Posada de la Paz M. Clinical findings. In: Toxic Oil Syndrome: Current Knowledge and Future Perspectives (Nadal J, Tarkowski S, eds). European Series No. 42. Copenhagen:World Health Organization, Regional Office for Europe, 1992;26-36.
10. Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine (Baltim) 72:285-295 (1993).
11. Kaufman LD, Izquierdo-Martínez M, Serrano JM, Gómez JJ. 12-Year followup study of epidemic Spanish toxic oil syndrome. J Rheumatol 22:282-288 (1995).
12. Gómez de la Cámera A, Posada de la Paz M, Abaitua-Borda I, Barainca-Oyagüe MT, Abraira-Santos V, Ruiz-Navarro MD, Terracini B. Health status measurement in toxic oil syndrome. J Clin Epidemiol 51:867-873 (1998).
13. Philen RM, Posada de la Paz M, Hill RH, Shurz HH, Abaitua Borda I, Gómez de la Cámara A, Kilbourne EM. Epidemiology of the toxic oil syndrome. Arch Toxicol Suppl:41-52 (1997).
14. Gómez de la Cámara A, Abaitua-Borda I, Posada de la Paz M. Toxicologists versus toxicological disasters: toxic oil syndrome, clinical aspects. Arch Toxicol Suppl:31-40 (1997).
15. Doll R. The Aetiology of the Spanish Toxic Syndrome: Interpretation of the Epidemiological Evidence. SPA/CEH 502. Copenhagen:World Health Organization, 1987.
16. Kilbourne EM, Bernert JT, Posada de la Paz M, Hill RH, Abaitua Borda I, Kilbourne BW, Zack MM. Chemical correlates of pathogenicity of oils related to the toxic oil syndrome epidemic in Spain. Am J Epidemiol 127:1210-1227 (1988).
17. Ventura Diaz M. Conventional analysis of the available samples of purportedly toxic oils. Grasas y Aceites 33:73-77 (1982).
18. Bernert JT, Kilbourne EM, Akins JR, Posada de la Paz M, Meredith NK, Abaitua-Borda I, Wages S. Compositional analysis of oil samples implicated in the Spanish toxic oil syndrome. J Food Sci 52:1562-1569 (1987).
19. Vazquez-Roncero A, Janer del Valle C, Maestro-Quran R, Graciane-Constante E. New aniline derivatives in cooking oils associated with toxic oil syndrome. Lancet 2:1024-1025 (1983).
20. Vazquez-Roncero A, Maestro-Duran R, Graciane-Constante E, Janer del Valle C. New aniline derivatives in oils related to the toxic syndrome. I: Fatty esters of 3-phenylamino-1,2-propanediol. Grasas y Aceites 35:15-21 (1984).
21. Schurz HH, Hill RH, Posada de la Paz M, Philen RM, Abaitua-Borda I, Bailey SL, Needham LL. Products of aniline and triglycerides in oil samples associated with the toxic oil syndrome. Chem Res Toxicol 9:1001-1005 (1996).
22. Posada de la Paz M, Philen RM, Abaitua Borda I, Diez Ruiz-Navarro M, Abraira Santos V, Pozo Rodríguez F, Pla Mestre R, Pollán Santamaria M, Sicilia Socias JM, Azpeitia Gamazo P, et al. Factors associated with pathogenicity of oils related to the toxic oil syndrome epidemic in Spain. Epidemiology 5:404-409 (1994).
23. Hill RH, Schurz HH, Posada de la Paz M, Abaitua-Borda I, Philen RM, Kilbourne EM, Head SL, Bailey SL, Driskell WJ, Barr JR. Possible etiologic agents for toxic oil syndrome: fatty acid esters of 3-(N-phenylamino)-1,2-propanediol. Arch Environ Contam Toxicol 28:259-264 (1995).
24. Posada de la Paz M, Philen RM, Schurz HH, Hill RH, Gimenez-Ribota O, Gómez de la Cámara A, Kilbourne EM, Abaitua-Borda I. Epidemiologic evidence for a new class of compounds associated with toxic oil syndrome. Epidemiology 10:130-134 (1999).
25. Aldridge WN. Experimental studies. In: Toxic Oil Syndrome: Current Knowledge and Future Perspectives (Nadal J, Tarkowski S, eds). European Series No. 42. Copenhagen:World Health Organization, Regional Office for Europe, 1992;63-93.
26. Nadal J, Tarkowski S, eds. Toxic Oil Syndrome: Current Knowledge and Future Perspectives (Nadal J, Tarkowski S, eds). European Series No. 42. Copenhagen:World Health Organization, Regional Office for Europe,1992
27. Stolk JM, Smith RP. Species differences in methemoglobin reductase activity. Biochem Pharmacol 15:343-351 (1966).
28. Welch RM, Conney AH, Burns JJ. The metabolism of acetophenetidin and N-acetyl-p-aminophenol in the cat. Biochem Pharmacol 15:521-531 (1966).
29. McLean S, Robinson J, Starmer GA, Thomas J. The influence of anaesthetic agents on the formation of methaemoglobin induced by aniline in cats. J Pharm Pharmacol 19:803-809 (1967).
30. Smith RP, Alkaitis AA, Sharer PR. Chemically induced methemoglobinemias in the mouse. Biochem Pharmacol 16:317-328 (1967).
31. Lahoz C, Rose NR, Robinson CJG. Immunology. In: Toxic Oil Syndrome: Current Knowledge and Future Perspectives (Nadal J, Tarkowski S, eds). European Series No. 42. Copenhagen:World Health Organization, Regional Office for Europe, 1992;143-152.
32. Gallardo S, del Pozo V, Cárdaba B, De Andrés B, Martín-Orozco E, Fernandez JC, Tramón P, Posada M, Abaitua I, Palomino P, et al. Immunological basis of toxic oil syndrome (TOS). Toxicology 93:289-299 (1994).
33. Del Pozo V, de Andrés B, Gallardo S, Cárdaba B, De Arruda-Chaves E, Cortegano MI, Jurado A, Palomino P, Oliva H, Aguilera B, et al. Cytokine mRNA expression in lung tissue from toxic oil syndrome patients: a TH2 immunological mechanism. Toxicology 118:61-70 (1997).
34. Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther 54:235-241 (1993).
35. Nebert DW, McKinnon RA, Puga A. Human drug-metabolism enzymes polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280 (1996).
36. Heim MH, Meyer U. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532 (1990).
37. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:773-776 (1990)
38. Skoda RC, Gonzalez F, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450 db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240-5243 (1988).
39. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-202 (1996).
40. Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA. Debrisoquine/spartine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558 (1991).
41. Graft T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxilation by DNA-test in healthy human volunteers. Eur J Clin Pharmacol 43:399-403 (1992).
42. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295 (1997).
43. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer associated Msp I polymorphism with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem 110:407-411 (1991).
44. Crofts F, Cosma GN, Currie D, Taioli E, Toniolo P, Garte SJ. A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 14:1729-1731 (1993).
45. Taioli E, Crofts F, Trachman J, Bayo S, Toniolo P, Garte SJ. Racial differences in CYP1A1 genotype and function. Toxicol Lett 77:357-362 (1995).
46. Seidegard J, Voracheck FJ, Pero RW, Pearson WR. Hereditary differences in the expresion of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297 (1988).
47. Pemble S, Schroeder KR, Spencer SF, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polimorphism. Biochem J 300:271-276 (1994).
48. Pearson WR, Voracheck W, Xu S, Berger R, Hart I, Vannais D, Patterson D. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet 53:220-233 (1993).
49. Blum M, Demierre A, Grant O, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88:5237-5241 (1991).
50. Hickman D, Sim E. N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans Biochem Pharmacol 42:1007-1014 (1991).
51. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling J, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581-592 (1995).
52. Lovlie R, Daly A, Idle JR, Steen VM. Characterization of the 16 + 9 Kb and 30 + 9 Kb CYP2D6 Xba I haplotypes Pharmacogenetics 7:149-152 (1997).
53. Aldridge WN. Mechanism and Concepts in Toxicology. Oxford:Taylor & Francis, 1996.
54. Dwyer DM, Strickler H, Goodman RA, Armenian HK. Use of case-control studies in outbreak investigations. Epidemiol Rev 16:109-123 (1994).
55. Lasky T, Stolley PD. Selection of cases and controls. Epidemiol Rev 16:6-17 (1994).
56. Agúndez JAG, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 55:412-417 (1994).
57. Ladona MG, Abildúa RE, Ladero JM, Román JM, Plaza MA, Agúndez JAG, Muñoz JJ, Benitez J. CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett 99:23-28 (1996).
58. Agúndez JAG, Martinez C, Olivera M, Ledesma MC, Ladero JM, Benitez J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 56:202-209 (1994).
59. Austin H, Hill H, Flanders WD, Greenberg RS. Limitations in the application of case-control methodology. Epidemiol Rev 16:65-76 (1994).
60. Posada de la Paz M, Philen RM, Abaitua Borda I, Sicilia Socias JM, Gómez de la Cámara A, Kilbourne EM. Toxic oil syndrome: traceback of the toxic oil and evidence for a point source epidemic. Food Chem Toxicol 34:251-257 (1996).
61. Maestro-Duran R, Ruiz-Gutierrez V, Vazquez-Roncero V. Estudio toxicológico en ratones de nuevos derivados de la anilina presentes en aceites tóxicos. Rev Toxicologia (Spain) 2:168-183 (1985).
62. Nelson SD. Arylamines and arylamides: oxidation mechanisms. In: Bioactivation of Foreign Compounds (Anders MW, eds). New York:Academic Press, 1985:349-374.
63. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29 (1-2):413-580 (1997).
64. Roots I, Hildebrandt AG, Hirner A, Heinemeyer G. High sensitivity of cytochrome P-450 reactions in human liver microsomes towards oleylanilide, the presumptive toxin in the Spanish oil epidemic 1981 [Abstract]. Naunyn-Schmildeberg's Arch Pharmacol (suppl):R-30(1982).
65. Berking C, Hobbs MV, Chatelain R, Meurer M, Bell SA. Strain-dependent cytokine profile and susceptibility to oleic acid anilide in murine model of the toxic oil syndrome. Toxicol Appl Pharmacol 148:222-228 (1998).
66. Ladona MG, Bujons J, Messeguer A, Ampurdanés C, Morató A, Corbella J. Biotransformation and clearance of 3-(phenylamino)propane-1,2-diol, a compound present in samples related to toxic oil syndrome in C57BL/6 and A/J mice. Chem Res Toxicol 12:1127-1137 (1999).
67. Ladona MG, Bujons J, Messeguer A, Ampurdanés C, Morató A. Unpublished data.
68. Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 107(suppl 5):693-700 (1999).
69. Von Schmiedeberg S, Fritsche F, Ronnau AC, Specker C, Golka K, Richter-Hintz D, Schuppe HC, Lehmann P, Ruzicka T, Esser C, et al. Polymorphism of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 455:147-152 (1999).
70. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 19(3):133-141 (1998).
71. Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G. Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 65:562-569 (1999).